{"entity":{"id":"francois-clement-bidard","kind":"person","name":"François-Clément Bidard","aka":[],"tldr":"Led PADA-1, the first trial to switch endocrine therapy on a rising ESR1 mutation in blood.","summary":"François-Clément Bidard is Head of Medical Oncology at Institut Curie and Professor at UVSQ Paris-Saclay. His specialisms are breast cancer, circulating tumour DNA, endocrine therapy and circulating tumour cells, with a focus on the oestrogen receptor in HR-positive, HER2-negative disease. He led PADA-1, the first trial to switch endocrine therapy on a rising ESR1 mutation detected in blood, reported in Lancet Oncology as a switch to fulvestrant and palbociclib during aromatase inhibitor therapy. He also led EMERALD, the Journal of Clinical Oncology trial of elacestrant versus standard endocrine therapy in advanced breast cancer. He pioneered ctDNA-guided treatment switching, and his publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bidard%20FC%5BAuthor%5D%20ESR1%20ctDNA"}],"tags":[],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":["liquid-biopsy"],"targets":["estrogen-receptor"],"drugs":["elacestrant","fulvestrant"],"companies":[],"institutions":["institut-curie"],"pathways":[],"terms":[],"trials":["emerald"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of Medical Oncology, Institut Curie; Professor, UVSQ Paris-Saclay","institutionId":"institut-curie","specialisms":["Breast cancer","Circulating tumour DNA","Endocrine therapy","Circulating tumour cells"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bidard%20FC%5BAuthor%5D%20ESR1%20ctDNA"}],"papers":[{"title":"Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1)","journal":"Lancet Oncology","year":2022,"doi":"10.1016/S1470-2045(22)00555-1"},{"title":"Elacestrant versus standard endocrine therapy for estrogen receptor-positive, HER2-negative advanced breast cancer (EMERALD)","journal":"JCO","year":2022,"doi":"10.1200/JCO.22.00338"}],"orcid":"0000-0001-5932-8949"},"route":"/people/francois-clement-bidard/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"}],"target":[{"id":"estrogen-receptor","kind":"target","name":"Estrogen receptor (ERα)","route":"/targets/estrogen-receptor/"}],"drug":[{"id":"elacestrant","kind":"drug","name":"Elacestrant","route":"/drugs/elacestrant/"},{"id":"fulvestrant","kind":"drug","name":"Fulvestrant","route":"/drugs/fulvestrant/"}],"institution":[{"id":"institut-curie","kind":"institution","name":"Institut Curie","route":"/institutions/institut-curie/"}],"trial":[{"id":"emerald","kind":"trial","name":"EMERALD","route":"/trials/emerald/"}]}}